Narcolepsy Type 1 with Cataplexy and Excessive Daytime Sleepiness — Next-Line Treatment After Monotherapy Failure
This protocol targets narcolepsy type 1 (NT1) in patients whose cataplexy and excessive daytime sleepiness remain inadequately controlled on a single-agent regimen. NT1 is the subtype in which cataplexy — a brief, sudden loss of muscle tone — occurs alongside the hallmark symptom of excessive daytime sleepiness.
Clinical Scenario
There are two primary classifications of narcolepsy: narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). The hallmark symptom is excessive daytime sleepiness, but only patients with NT1 experience cataplexy. Cataplexy is a brief, sudden loss of muscle tone. This protocol addresses NT1 patients in whom both EDS and cataplexy require ongoing management.
Previous Line — Escalation Trigger
The preceding treatment line used either sodium oxybate monotherapy or pitolisant monotherapy. Escalation to this protocol is indicated when single-agent therapy fails to achieve adequate control of excessive daytime sleepiness and cataplexy — including failure to reduce the Epworth Sleepiness Scale score to no more than 10.
Next-Line Approach (Partial Overview)
This protocol employs combination therapy — two agents used together when monotherapy no longer controls symptoms. Many patients ultimately require multiple medications to manage narcolepsy, even when a broadly effective agent has already been tried as a first step.
The full regimen, sequencing, and clinical decision points are available via the complete protocol below.
Goal: Stabilised EDS and cataplexy control
References
DOI: 10.9740/mhc.2025.12.258
- There are 2 primary classifications of narcolepsy, narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2).
- The hallmark symptom is excessive daytime sleepiness (EDS), but only patients with NT1 experience cataplexy.
- Cataplexy is a brief, sudden loss of muscle tone.
- Many patients ultimately require multiple medications to manage narcolepsy even when a medication that is usually effective across a wide range of symptoms, such as an oxybate, is used.
- Pitolisant was added to her regimen, and her symptoms have remained stable.
View source ↗